Hip fracture mortality in patients co-infected with coronavirus disease 2019 : a comparison of the first two waves of the United Kingdom pandemic during the pre-vaccine era
© 2021. The Author(s) under exclusive licence to SICOT aisbl..
AIMS: In the UK, deaths associated with COVID-19 have occurred in two waves. Evidence has shown an increase in 30-day mortality for hip fracture patients co-infected with COVID-19. However, there are no studies analysing mortality trends between the first two waves of the UK pandemic. Additionally, hospital versus community acquired COVID-19 infection between the two waves has not been analysed. Furthermore, predictive factors of 30-day mortality have not been fully evaluated.
METHODS: Data from two audits conducted by the CHIP collaborative group were used: a published regional audit in England of nine hospitals providing the COVID-19 negative cases and an unpublished UK national audit of 43 hospitals, which provided the COVID-19 positive cases. Data collection for the COVID-19 positive cases was from 23 March to 31 December 2020. September 1, 2020 was used to define the transition between the two waves.
RESULTS: There were 517 COVID-19 positive hip fracture patients and 1445 COVID-19 negative hip fracture patients. Overall, 30-day mortality rates were 5.7% in the COVID-19 negative group and 22.4% in the COVID-19 positive patients (p < 0.001). A difference in survival function between the first and second waves was found (p = 0.038). To allow for significant demographic differences, a matched analysis of 185 patients found a 26.5% 30-day mortality in the first wave compared to 21.1% in the second wave (p = 0.222). Within the COVID-19 positive groups, the virus was hospital acquired in 66.7% of cases in the first wave and 72.8% of cases in the second wave (p = 0.130). Independent predictors of mortality were found to include COVID-19 positive status, AMTS ≤ 6, male gender and age.
CONCLUSION: There was a reduction in 30-day mortality for hip fracture patients co-infected with COVID-19 between the two UK pandemic waves but this was not statistically significant. There was no reduction in hospital acquired COVID-19 infection between the two waves.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
International orthopaedics - 46(2022), 2 vom: 30. Feb., Seite 171-178 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rashid, Fatima [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 28.01.2022 Date Revised 16.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00264-021-05269-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335351832 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335351832 | ||
| 003 | DE-627 | ||
| 005 | 20231225225633.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00264-021-05269-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335351832 | ||
| 035 | |a (NLM)34999906 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rashid, Fatima |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hip fracture mortality in patients co-infected with coronavirus disease 2019 |b a comparison of the first two waves of the United Kingdom pandemic during the pre-vaccine era |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.01.2022 | ||
| 500 | |a Date Revised 16.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s) under exclusive licence to SICOT aisbl. | ||
| 520 | |a AIMS: In the UK, deaths associated with COVID-19 have occurred in two waves. Evidence has shown an increase in 30-day mortality for hip fracture patients co-infected with COVID-19. However, there are no studies analysing mortality trends between the first two waves of the UK pandemic. Additionally, hospital versus community acquired COVID-19 infection between the two waves has not been analysed. Furthermore, predictive factors of 30-day mortality have not been fully evaluated | ||
| 520 | |a METHODS: Data from two audits conducted by the CHIP collaborative group were used: a published regional audit in England of nine hospitals providing the COVID-19 negative cases and an unpublished UK national audit of 43 hospitals, which provided the COVID-19 positive cases. Data collection for the COVID-19 positive cases was from 23 March to 31 December 2020. September 1, 2020 was used to define the transition between the two waves | ||
| 520 | |a RESULTS: There were 517 COVID-19 positive hip fracture patients and 1445 COVID-19 negative hip fracture patients. Overall, 30-day mortality rates were 5.7% in the COVID-19 negative group and 22.4% in the COVID-19 positive patients (p < 0.001). A difference in survival function between the first and second waves was found (p = 0.038). To allow for significant demographic differences, a matched analysis of 185 patients found a 26.5% 30-day mortality in the first wave compared to 21.1% in the second wave (p = 0.222). Within the COVID-19 positive groups, the virus was hospital acquired in 66.7% of cases in the first wave and 72.8% of cases in the second wave (p = 0.130). Independent predictors of mortality were found to include COVID-19 positive status, AMTS ≤ 6, male gender and age | ||
| 520 | |a CONCLUSION: There was a reduction in 30-day mortality for hip fracture patients co-infected with COVID-19 between the two UK pandemic waves but this was not statistically significant. There was no reduction in hospital acquired COVID-19 infection between the two waves | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hip fracture | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Pandemic | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Hawkes, David |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmood, Aatif |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, William James |e verfasserin |4 aut | |
| 700 | 0 | |a CHIP collaborative group |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Khan, Shoaib |e investigator |4 oth | |
| 700 | 1 | |a As-Sultany, Mohammed |e investigator |4 oth | |
| 700 | 1 | |a Nagy, Mathias |e investigator |4 oth | |
| 700 | 1 | |a Reddy, Gautam |e investigator |4 oth | |
| 700 | 1 | |a Limb, Richard |e investigator |4 oth | |
| 700 | 1 | |a Zreik, Nasri |e investigator |4 oth | |
| 700 | 1 | |a Mahomed, Ebrahim |e investigator |4 oth | |
| 700 | 1 | |a Howard, Josh |e investigator |4 oth | |
| 700 | 1 | |a Palaparthy, Prakash |e investigator |4 oth | |
| 700 | 1 | |a Shah, Aadam |e investigator |4 oth | |
| 700 | 1 | |a Mathias, Calvin |e investigator |4 oth | |
| 700 | 1 | |a Wilson, Graeme |e investigator |4 oth | |
| 700 | 1 | |a Shetty, Vishvas |e investigator |4 oth | |
| 700 | 1 | |a Saeed, Abu |e investigator |4 oth | |
| 700 | 1 | |a Cuthbert, Rory |e investigator |4 oth | |
| 700 | 1 | |a Patnaik, Surendra |e investigator |4 oth | |
| 700 | 1 | |a Chan, Carol |e investigator |4 oth | |
| 700 | 1 | |a Zaib, Jehan |e investigator |4 oth | |
| 700 | 1 | |a Hasan, Yusuf |e investigator |4 oth | |
| 700 | 1 | |a Sykes, Mark |e investigator |4 oth | |
| 700 | 1 | |a Pujol, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Osarumwense, Donald |e investigator |4 oth | |
| 700 | 1 | |a Adamczyk, Aleksandra |e investigator |4 oth | |
| 700 | 1 | |a Cash, Tom |e investigator |4 oth | |
| 700 | 1 | |a Bawa, Akshdeep |e investigator |4 oth | |
| 700 | 1 | |a Havenhand, Tom |e investigator |4 oth | |
| 700 | 1 | |a Bashir, Muhammed Amer |e investigator |4 oth | |
| 700 | 1 | |a Critchley, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Jaly, Ibrahim |e investigator |4 oth | |
| 700 | 1 | |a Mohamed, Muyed |e investigator |4 oth | |
| 700 | 1 | |a Weiyun, Wayne Ng |e investigator |4 oth | |
| 700 | 1 | |a Gibbon, Anthony |e investigator |4 oth | |
| 700 | 1 | |a Mudiganty, Srikanth |e investigator |4 oth | |
| 700 | 1 | |a Ali, Salman |e investigator |4 oth | |
| 700 | 1 | |a Rias, Shan |e investigator |4 oth | |
| 700 | 1 | |a Nabi, Wahidun |e investigator |4 oth | |
| 700 | 1 | |a Ong, Jason |e investigator |4 oth | |
| 700 | 1 | |a Trowbridge, Sam |e investigator |4 oth | |
| 700 | 1 | |a Harris, Mark |e investigator |4 oth | |
| 700 | 1 | |a Gandhi, Sanket |e investigator |4 oth | |
| 700 | 1 | |a Armoni, Panagiotis |e investigator |4 oth | |
| 700 | 1 | |a Khanom, Shayra |e investigator |4 oth | |
| 700 | 1 | |a Lebe, Moritz |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t International orthopaedics |d 1979 |g 46(2022), 2 vom: 30. Feb., Seite 171-178 |w (DE-627)NLM000959146 |x 1432-5195 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2022 |g number:2 |g day:30 |g month:02 |g pages:171-178 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00264-021-05269-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2022 |e 2 |b 30 |c 02 |h 171-178 | ||